Radiomedix,Inc. is a privately held biotechnology company founded in 2006 to develop and commercialize technology and products which will enable on-site and on-demand access to Positron Emission Tomography (PET). RadioMedix is developing its own chelation technology and new imaging conjugates, GlucoMedix and OncoMedix, which have the potential to significantly improve diagnosis and treatment monitoring for a variety of cancers. RadioMedix’s automated SmartMedixTM system, coupled with a small generator producing a PET isotope such as Gallium-68 (Ga), will permit users to generate and label PET radiotracers on-site. It will significantly reduce cost of radiosynthesis that can be performed without the need for costly cyclotron facilities. RadioMedix has developed novel products for Nuclear Medicine researchers and clinicians. These products will provide researchers and clinicians unique solutions to address the limitations of 18F Chemistry and cyclotron-produced isotopes. RadioMedix has established state-of-the-art laboratories that are available for contract research. Our Micro-PET Imaging Center, cGMP isotope manufacturing suite, isotope development laboratories and expert scientific medical staff are ready to assist you in your project.